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Differential CYPlAl inducibility, reflectingvariations in aromatic hydrocarbonreceptor (AHR)
affinityamonginbred mouse strains, is an important determinant ofenvironmental toxicity.We
took advantage oftheAirpolymorphism in C57BL16 and DBA/2 mice to develop an oligonu-
deotide-hybridization screening approach for the rapid identification ofDNA sequence differ-
ences betweenAiralleles. Oligonudeotides containing single-base changes at polymorphic sites
wereimmobilizedonasolidsupport andhybridizedwithC57BL/6 orDBA/2AHRcDNAradi-
olabeled probes. The observed hybridization patterns demonstrate that this approach can be
used to detect nudeotide differences in theAircodingregionwith veryhighaccuracy. In paral-
lel experiments, we used a yeast two-hybrid system to assess phenotypic differences in AHR
function. AHRactivation, asmeasuredby13-galactosidase reporteractivityin Saceharomyces cere-
visiaestrain SFY526, was determinedfollowing treatmentwithvaryingdoses oftheAHRligand
P-naphthoflavone (BNF). We found that the C57BL16 AHRhas about a 15-fold higher affinity
for BNF than the DBAI2 AHR, in much better agreement with results reported for whole-aii-
mal studies than the values observed by in vitro ligand-binding assays. Using C57BLI6 and
DBA/2 AHR chimeric proteim, we also confirmed the previously reported observation that an
A375Vchange isprincipallyresponsible forthehigh- tolow-affinityAHRphenotype. Therehas
been no straightforward method to reliably and reproducibly phenotype large numbers of
humans for CYPlAl inducibility orAHR affinity. Screening human AHR cDNAs byoligonu-
deotide-hybridization and yeast two-hybrid methodologies will be invaluable for the rapid and
unequivocal determination ofchanges in DNAsequenceandreceptor-ligand affinitiesassociated
with human AHRpolymorphisms. Key work aromatic hydrocarbon (Ah) receptor, mouse Ahr
gene polymorphism, oligonudeotide hybridization, yeast two-hybrid system, f-naphthoflavone.
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One ofthe most challenging questions facing
environmental health research today is the
identification ofgenotype changes associated
with phenotypes of increased resistance or
susceptib ity to toxic environmental agents.
Environmental pollutants generate varying
degrees of response in an exposed popula-
tion, often due to polymorphisms in the
genes controlling the molecular mechanisms
of the toxic response. For example, a clear
genetic component exists in the susceptibility
of mouse strains to many halogenated aro-
matic hydrocarbons (HAHs) and nonhalo-
genated polycyclic aromatic hydrocarbons
(PAHs), such as 2,3,7,8-tetrachlorodibenzo-
p-dioxin (dioxin) and benzo(a)pyrene (BaP),
respectively. These two environmental com-
pounds exhibit ahigh degree oftoxicity. BaP
is a potent carcinogen in animals and a sus-
pected carcinogen in humans (1). Dioxin is
associated with a variety ofsystemic effects,
including immunosuppression, cleft palate,
and tumor promotion in animals, and chlor-
acne, immunosuppression, and possibly can-
cer and heart disease in humans (2,3). There
is no instance known so far in which dioxin
or BaP toxicity or carcinogenesis in laborato-
ry animals is not mediated by the aromatic
hydrocarbon receptor (AHR), a transcrip-
tional regulator ofxenobiotic-metabolizing
enzymes encoded by the mammalian AHR
gene (4,5).
A mouse Ahr polymorphism is known
to be responsible for the variation in sus-
ceptibility to PAHs and HAHs (6-8). Four
distinct mouse Ahr alleles have now been
characterized, each encoding receptor pro-
teins with differing ligand affinities (9).
The AhA'-1, Ahrb-2, and Ahrb-3 alleles code
for AHRs with higher affinity than the
AHR encoded by the Ahrt allele (). The
AhrbJ1 allele occurs in C57, C58, and
MA/My inbred strains; the Ahtb-2 allele is
carried by the C3H, BALB/cBy, and A
inbred strains; the Ahr'-3 allele exists in
Muscaroli, Musspretus, and MOLF/Ei; and
theAhAd allele occurs inAKR, DBA/2, and
129 strains (9).
Ahr nucleotide differences, and corre-
sponding AHR amino-acid changes
between the C57BL/6 (B6) and DBA/2
(D2) mouse strains that carry theAhA'-1 and
Ahkd alleles, respectively, have been studied
extensively (9-15). An A375V change has
been reported to confer most of the
observed phenotypic differences between B6
and D2 (15). With hepatic cytosol from B6
and D2 mice, ligand-affinity differences
were found to range between 4- and 10-fold
for the B6 and D2 AHRs (1618, whereas
ligand-affinity differences range between 2-
and 6-fold for the B6 and D2 AHRs when
cDNA-expressed AHRs are studied (9,15).
These in vitro ligand-binding assays appear
not to accurately reflect the in vivovariability
in this polymorphism, however, because the
B6-D2 differences in hepatic aryl hydrocar-
bon hydroxylase (CYPlA1) inducibility in
the intact mouse are much larger-in the
order of15- to 30-fold (6-8,15P.
Many ofthe toxic effects ofAHRligands
observed in mice also occur in exposed
human populations, in which a large amount
ofinterindividual variability is seen; however,
a DNA-based explanation of the human
AHRpolymorphism is still to be determined.
CYPlAl inducibiityvaries bymore than 30-
fold in humans (20-23), and Scatchard plot
analyses of 106 human placental samples
have shown a >35-fold difference in AHR
affinity between the highest and lowest phe-
notype (24,25), yet there has not been any
direct correlation established between the
degree ofCYPlA1 inducibility and the varia-
tion in AHRaffinity in humans (26-254. No
nucleotide or amino acid change in the
human AHR has been unequivocally associ-
ated with ligand variability. Substitution of
alanine for valine at position 381 (equivalent
to position 375 in the mouse) was shown to
increase ligand affinity several-fold in an in
vitro cDNA-expression binding assay (15);
however, the human AHR protein from the
HepG2 andA431 cell lines, aswell as from at
least eightindividuals, contains valine at posi-
tion 381 in all cases (15,22,26-254. Another
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nucleotide change in exon 2 of the human
AHR gene has been reported (29), but no
phenotypic changes associated with this
polymorphismwere examined.
Progress in correlating any human AHR
genotype with variations in the AHR phe-
notype has been hindered bythe lackofeffi-
cient methods for screening large numbers
of individuals. Recently, reverse transcrip-
tase-polymerase chain reaction (RT-PCR)
has been successful for rapidly sequencing
portions ofthe AHR gene (22,29), but this
approach has been limited to small groups
ofindividuals and may be too cumbersome
for identification of nucleotide changes in
large populations. Approaches that rely on
oligonudeotide hybridization (30), however,
mayprovide a solution to this problem, par-
ticularly in light of the recent advances in
DNAchip technology (31).
Detection ofnudeotide differences must
be coupled to the analysis ofresulting func-
tional changes in order to assess the relevance
ofany given polymorphism to environmen-
tally related disease. In the case ofthe AHR,
the use ofmammalian tissue culture systems
forthispurpose has clearlyproven to be unre-
liable. For example, expression ofexogenous
AHR in AHR-deficient CV-1 African green
monkey kidney epithelial cells and mouse
hepatoma c35 cells results in high basal
CYPlA1 activity and low inducibility
(32-34), possibly due to the presence ofan
endogenous AHR ligand (35); therefore, the
expression ofexogenous AHR in cell culture
would notbe useful forphenotypic character-
ization of the human AHR. A widely used
method forthephenotypic analysis ofhuman
AHR function has been the mitogen-activat-
ed lymphocyte culture assay for CYPlA1
induction (36). Implementation of this
method is not trivial, with many laboratories
experiencing difficulties in reproducibility
(37,38). These findings underscore the
importance ofdeveloping a reliable, efficient,
and noninvasive test to determineAHRphe-
notype inlargehumanpopulations.
The yeast Saccharomyces cerevisiae may
provide the means for such a quantitative
phenotyping test; in contrast to AHR-defi-
cient mammalian cell lines, expression of
exogenous AHR in yeast generates a highly
sensitive detection system for the analysis of
AHR activation (34,39-41). In this report,
we have used the well-characterized Ahr
polymorphism between B6 and D2 mice to
optimize an oligonucleotide-hybridization
screening approach for the identification of
Ahr nucleotide changes and to develop a
yeast two-hybrid approach forthe functional
analysis ofthecorrespondingAHRprotein.
Materials and Methods
Sequencing by hybridization. Twelve sets of
four 21-residue oligonucleotides (Table 1),
for a total of48 target oligonucleotides, were
Table 1. Oligonucleotides forthe detection ofmouse Ahrpolymorphism
NT
2038
2198
2303
2326
2512
2594
2679
2687
2747
3098
3330
3336
AhrAllele
b-1
d
b-lid
b-i
d
b-i
d
b-1
d
b-1
d
b-i
d
b-1
d
b-i
d
b-1
d
b-i
d
b-1
d
Oligonucleotide sequence
TACATCATCGCCACTCAGAGA
T
CAATACGCACCAAAAGCAACA
CCATCTATCTGTGTCCTCCTT
A
AGCCCTGCGCTGTTAGACAGC
C
GACTTGTACAGCATCATGAGG
A
ACTCCACCGCTGCTGGTGAGG
C
TTCAACTGCTGAACTCGGC
A
TGCTGAACTCGGCTTGCCAGC
C
AGCGCCTGCAACTAGAGCAAC
T
ATTTTGAACCGTCCCTGCATC
A
GGTGCAGAGTTGAGGTGTTTT
C
GAGTTGAGGTGTTTCAATGA
A
62
60
60
62
60
68
70
62
60
70
72
62
60
68
68
66
66
62
60
62
64
58
56
AA
Alanine
Valine
Proline
Leucine
Leucine
Leucine
Proline
Serine
Asparagine
Alanine
Alanine
Leucine
Methionine
Serine
Serine
Glutamine
Glutamine
Proline
Proline
Opal
Arginine
Isoleucine
Abbreviations: NT, nucleotide position within the cDNA sequence(121; To, theoretical dissociation temperature ofthe per-
fect hybrid calculated from the sequence; AA, amino acid encoded by the corresponding codon at the polymorphic site.
Oligonucleotides (21-mersl were synthesized for 10 polymorphic sites in the coding region ofthe mouseAhrgene, 1 poly-
morphic site outside the coding region, and 1 control site ofsequence identity between C57BL/6 andDBAN2. The sequence
shown corresponds to the Ahr-1 allele. In each case, the middle nucleotide (in bold) was replaced by each of the other
three nucleotides, one of which matches that of the Ahdallele (shown below each sequence); the other two oligonu-
cleotides of each set are not shown. At positions 2679, 2687, 3330, and 3336-due to the proximity of two Ahrb-/Ahid
polymorphic sites-theAhrdconsensus oligonucleotides contain an additional nucleotide change.
commercially synthesized (Bio-Synthesis,
Inc., Lewisville, TX) forhybridization experi-
ments. Each set corresponded to 1 ofthe 11
sites at which theAhM' andAht4 alleles dif-
fered, plus 1 control site atwhich both alleles
were identical. The fouroligonudeotides in a
set differed only by the middle 11th residue,
which containedA, C, G, or T. For each set,
one oligonucleotide matchedAhrb-1, another
matchedAhr*',and the other two matched
neither.
The sequences and theoretical dissocia-
tion temperatures of 23 ofthe 48 oligonu-
deotides are shown inTable 1. Five ofthe 11
polymorphic sites encode amino acid
sequence changes. Oligonucleotides were
transferred to aNytran membrane (Schleicher
& Schuell, Keene, NH) using a slot-blotting
apparatus (Bio-Rad, Richmond, CA). Each
oligonudeotide (1 pg) wasapplied to aslotby
filtration under vacuum, washed with 0.5 M
sodium phosphate buffer (pH 7.0), and UV
cross-linked to the membrane. Membranes
werehybridizedwithB6, D2, oreach ofeight
chimeric AHR cDNA probes (containing
combinations ofthe polymorphic sites from
the Ahrb-1 and Ah?4alleles). The chimeric
cDNAs were constructed using standard
recombinant DNA techniques (12,35), and
encode the amino acid changes shown in
Figure 1. cDNA probes were labeled with
[32P]dCTP (Amersham, Arlington Heights,
IL) by nick translation (Gibco-BRL, Inc.,
Rockville, MD). Membranes were prehy-
bridized in a buffer containing 6X SSC (0.9
M NaCI, 0.09 M sodium citrate), 1% sodi-
umdodecylsulfate, and 100 jg denaturedcalf
thymus DNA per milliliter. Hybridizations
were carried out in the same buffer, with the
addition of 1 x 106 dpm/ml [32P]-labeled
probe. Following overnight hybridization at
temperatures ranging from 460C to 600C,
Figure 1. Schematic structure of C57BL/6 (B6),
DBAN2 (D2), and chimeric B6-D2 AHR constructs
used inthese studies. Abbreviations: A, alanine;V,
valine; L, leucine; P, proline; S, serine; N, glutamic
acid; M,methionine; R,arginine.
*Represents the opaltermination codon.
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membranes were washed at the hybridization
temperature in 6X SSC, 0.1% sodium dode-
cylsulfate, and exposed to x-ray f'ilm.
Hybridization intensities were quantified by
phosphorimaging in a Storm 860 (Molecular
Dynamics).
Yeastplarmid constructs andyeast trans-
formation. The B6, D2, and eight chimeric
AHR cDNAs, cloned in the eukaryotic
expression vector pCDNAI/ Amp (35), were
excised from this vector and cloned into the
trp' yeast expression vector pGBT9
(ClonTech, PaloAlto, CA) in-fr-ame with the
DNA binding domiain ofGAL4, resulting in
each of 10 different pGBT9AHR plasmids.
The AHR nuclear translocator (ARNT) full-
length cDNA was excised from pCDNAneol
ARNT and cloned into the keu+ yeast vector
pGAD424 (ClonTech) in-frame with the
GAL4 transactivation domain, resulting in
plasmid pGAD424ARNT. S. cerevisiae strain
SFY526 (leu, tPp-) was grown in YEPD medi-
um (10 g/l yeast exract, 2g/l peptone, 20 g/l
dextrose, 253 mg!1 adenine, 133 mg/l uracil)
and transformed by electroporation with
pGAD424ARNT and plated on yeast mini-
mal medium (1 M sorbitol, 1.7 gyeast nitro-
gen base/1, 1 g/l ammonium sulfate, 10 g/l
succinic acid, 6 g/l NaGH, 20 g/l dextrose,
2% (w/v) agar, and a cocktail of essential
amino acids minus leucine). After incubation
at 300C, individual colonies were grown in
liquid medium (same medium as above but
without sorbitol or agar), transformed with
each ofthe pGBT9AHRplasmids by electro-
poration, and plated on minimal medium
minus leucine and tryptophan. Several indi-
vidual colonies from these plates were then
used for theAHRactivation studies.
P3-Galactosidase assays. Minimal medi-
um minus leucine and tryptophan was inoc-
ulated with individual yeast colonies and
grown overnight at 30C to saturation.
Dioxin, 03-naphthoflavone (BNF), or BaP
(dissolved in dimethylsulfoxide) was then
added to fresh medium to final concentra-
tions ranging from 10-10 to i0-5 M, and the
medium was inoculated with an aliquot of
the saturated yeast cultures to an GD600
(optical density) ranging between 0.05 and
0.2. Control cultures were treated with an
equivalent amount of dimethylsulfoxide
vehicle. All cultures were grown 8-12 hr and
harvested by centrifugation. The cells were
washed in a buffer (containing 100 mM
HEPES, 150 mM NaCI, 4.5 mM hemi-
magnesium salt of L-aspartate, 10 mg/ml
bovine serum albumin, and 0.05% Tween
20) andlysedbyfreezing inliquidnitrogen.
P-galactosidase activity was determined
by adding 2.2 mM chlorophenol red-P-D-
galactopyranoside (CPRG) and incubating
the reaction for varying periods of time at
room temperature. The colorimetric reaction
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Figure 2. Hybridization of C57BL/6 (B6) and DBA/2 (D2) cDNA probes to oligonucleotide arrays spanning
all polymorphic sites in the Ahrb-1 and Ahrd1alleles. The hybridization temperature was 56C. The allele,
the nucleotide (NT), and its position in the AHR cDNA are indicated adjacent to a representative example
of a hybridization experiment. Hybridization intensities were quantitated for all probes, and the mean val-
ues relative to the maximum for each oligonucleotide in a set are shown.
was stopped by addition ofZnCl2 to a final
concentration of 1 mM; P3-galactosidase
activity was assessed by measuring the
absorbance at 578 nm and calculated using
theequation:
IP-galactosidase activity = (1,000 X
A7lA6 xcell volume (ml) X time(mm)].
Results
Detection ofsingle Ahr nucleotide changes
by oligonucleotide hybridization. To test
whether the oligonucleotide-hybridization
screening approach could be used to identi-
fy nucleotide changes reflecting amino acid
differences, we hybridized B6, D2, and
chimeric AHR cDNA probes to an
oligonucleotide array containing single-base
substitutions at all mouse Ahrpolymorphic
sites, plus the one control invariant site.
Representative hybridization results are
shown in Figure 2 for each ofthe 12 sets of
four oligonucleotides. The relative
hybridization intensities of all the probes
were calculated for each oligonucleotide
array position, and the means for a given
nucleotide position are shown adjacent to
the corresponding slot. In all cases,
hybridization was strongest with the correct
oligonucleotide, although we detected vary-
ing degrees of hybridization to the other
three oligonucleotides. Hybridization to
Ahrb- sequences by 11 ofthe 12 B6 probes
and hybridization to Ahid sequences by 10
of the 12 D2 probes occurred with the
highest degree of specificity. Nonspecific
binding was less than 19% ofmaximum for
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all positions except for olig
position 2038-towhich, in
oligonucleotide containing
nucleotide, oligonucleotide5
and A also hybridized, altho
efficiencies of 0.85 and 0.4
Of the other two, two pro
one at the correct T and t
were observed for nudeotide
At position 3336, very litti
took place, possibly becausi
cleotide also carried a secc
change at position 3330. N
quantitation showed that h
the correct oligonucleotide,
this position, was the stronge
All hybridization experin
Figure 2 were conducted at
found that the dissociation ti
each ofthe 48 oligonucleoti4
ly (Table 1). We tested whi
hybridizations that generat
results could be resolved by
hybridization temperature.
Figure 3 shows the resul
tions conducted at three othi
for oligonudeotides spanning
hybridized with both B6 and
for oligonucdeotides spanninE
hybridized with the D2 prob
the hybridization temp(
hybridization was strongest
Ahr
Probe NT Alleles
.2838
C b-1i
BB a
T d
A
-s
c
02 6
T
A
460
;onudeotides at oligonucleotide. Ambiguity for the Ahrt-1
addition to the consensus oligonudeotide at position 2038
the correct C was resolved as the hybridization tempera-
s containing G ture was increased to approach the dissocia-
ugh with lower tion temperature. For the D2 cDNA
0, respectively. hybridization at this position, two of the
tminent bands, nonspecific bandswere resolved, but no dear
he other at G, improvement in discrimination for the other
position 2038. twowas seen. Hybridization ofD2 cDNAto
e hybridization the oligonucleotides spanning position 3336
,e this oligonu- was unambiguous at 46°C, but the overall
rnd nucleotide intensitywas greatlydecreased as the temper-
otwithstanding, ature was increased, reflecting the lower dis-
ybridization to sociation temperature due to the presence of
containing A at a second nudeotide change in the consensus
st. oligonucleotide atthisposition. Wecondud-
nents shown in ed that the hybridization patterns clearly
56C, but we show that each probe has a strong preference
emperatures for for the oligonucleotide with a perfect
des differ wide- sequence match and that this oligonu-
Lether the three cleotide-hybridization technology is capable
ted ambiguous ofdetecting single-nudeotide changes with a
modifying the high degreeofaccuracy.
TheAHR is ligandresponsive in ayeast
ts ofhybridiza- two-hybrid system. To determine the
Ler temperatures capacity of various ligands to activate the
7 position 2038 AHR in a yeast two-hybrid system, we
D2 probes and transformed yeast strain SFY526 carrying
position 3336 pGAD424ARNT with pGBT9AHR vec-
te. Regardless of tors encoding B6 or D2 AHR (Fig. 4).
erature used, Cultures were treated with varying concen-
for the correct trations of dioxin, BNF, or BaP ranging
from 10-10 to 10-6 M and assayed for 0-
M0 f galactosidase activity. The AHR was acti-
vated by all three ligands in a dose-depen-
dent manner. At 10-6 M dioxin treatment
resulted in a sixfold increase ofI-galactosi-
dase activity, whereas BNF, and BaP
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Figure 3. Resolution of hybridization ambiguities
by changing the hybridization temperature.
Oligonucleotides spanning positions 2038 or 3336
were hybridized at 46°C, 54°C, and 60°C to the
C57BL/6 (B6) and DBA/2 (D2) cDNA probes.
Position, alleles, and hybridization temperatures
are indicated.
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pyrene. AZ
increases (
trols. Each
deviation of
caused 16- and 19-fold increases, respec-
tively. At any ligand concentration tested,
we found that activation of the B6 AHR
was greater than that of the D2 AHR,
regardless ofwhich ligand was used (data
not shown). The low levels ofinduction by
dioxin at doses 1,000-fold higher than
those needed in mammalian cells are prob-
ably due to low permeability ofyeast cells
for very hydrophobic compounds. These
results confirm workby others (34,39-41),
demonstrating that a yeast two-hybrid sys-
tem can be used to assess ligand-dependent
activation oftheAHR.
Quantitation ofAHRligandaffinity in
theyeast two-hybrid system. The observa-
tion that the AHR is ligand responsive in
yeast (Fig. 4) led us to test whether the
yeast two-hybrid assay could be used to
assess functional differences in AHR phe-
notype, i.e. variability in ligand affinity.
Using doses ofBNF ranging from 10-10 to
10-5 M, we found that BNF activates the
B6 AHR at a dose approximately 15-fold
lower than the D2AHR (Fig. 5A).
To identifyamino acid changes responsi-
ble for this difference in induction levels,
dose-response experiments were conducted
with the chimeric AHR constructs (illustrat-
ed in Fig. 1). We found aclearbimodality in
dose-response curves of the different
chimericAHRproteins (Fig. 5B). Regardless
ofother changes, all chimeras carrying ala-
nine (Ala)-375 responded in a fashion simi-
lar to that of the B6 receptor, whereas
chimeras containing valine (Val)-375
responded like the D2 receptor. In addition,
plateau values at the higher doses were 1.5-
to 2-fold higher for the B6-like chimeras
(data notshown).
Dose-response data were fitted to a
four-parameter function to estimate the dose
capable ofgenerating the half-maximal acti-
vation ofthe f-galactosidase reporter gene
(EC50). Table 2 presents theEC50 values for
B6, D2, and all eight AHR chimeras. AHR
proteins carrying Val-375 were found to
exhibit 14- to 24-fold higher EC50 values
thanAHRproteins containingAla-375.
Discussion
.'.We have shown in this report that oligonu-
deotide hybridization screening can be effec-
tively used to identify mouse Ahrnudeotide
TCDD BNF BaP differences with a high degree ofsuccess and reliability. From an array of48 oligonu-
*galactosidase activity following treat- deotides containing individual base substitu-
ast with three aromatic hydrocarbon tions at 11 polymorphic sites, specific
ligands at three concentrations. hybridization was evident for 11 ofthe 12
ns: TCDD, 2,3,7,8-tetrachlorodibenzo- AO'lallelesitesand 10of12Ahrallelesites.
NF, 3-naphthoflavone; BaP, benzo(a)- We have also shown thathybridization to the ssay results are reported as fold nave olsonotdf th e otOthe over dimethylsulfoxide-treated con- incorrect oligonudeotide for the other three
bar represents the mean ± standard sites occurred-to varying degrees, causing
threesamples. less-than-definitive results-for two reasons.
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use ofsuboptimal hybridization temperature
andclose proximityoftwopolymorphic sites.
Our results demonstrate thepowerofthis
method to identify sequence polymorphisms
without the need for DNA sequencing.
Although this is the first report oftheapplica-
tion of oligonudeotide hybridization screen-
ing of the Ahr gene, this approach has been
usedsuccessfully to detectpolymorphic alleles
ofseveral genes, induding S-globin, HLA-A,
BRCAI, and ,B-thalassemia (42-46).
We envision the application ofmodifica-
tions ofthis method (e.g., DNA chip tech-
nology) for the rapid and unequivocal
screening ofthe humanAHRgene polymor-
phism in a large number ofindividuals. The
complete 2,547-nudeotide coding sequence
ofthe human AHR cDNA could be repre-
sented in an array of849 21-mer sequential
oligonucleotides, each beginning three
nucleotides after the previous one. Any
polymorphism, detected by absence of
hybridization to the test probe, would be
present in seven (21/3) sequential oligonu-
cleotides. Inclusion of control and test
probes labeled with different fluorescent
dyes in the same hybridization reaction
would provide a rapid and efficient means of
detecting possible polymorphisms. Dozens
of samples could be processed in a single
day. Resolution ofambiguities and determi-
nation of the actual nucleotide present at a
polymorphic site could then be determined
simply by direct sequencing of the corre-
sponding short stretch ofDNA, thus greatly
decreasing the cost and time needed for
screening alarge numberofsamples.
We also have also demonstrated in this
report the usefulness ofa yeast two-hybrid
assay to quantitate the mouse AHR pheno-
type, i.e., its ligand affinity. The phenotyp-
ic variation, ranging from 15- to 30-fold
differences, between the B6 and D2 AHR
proteins in the intact animal was shown to
be accurately reflected in the yeast two-
hybrid system.
As measured by P-galactosidase reporter
activity in this assay, the EC50 for BNF is
about 15-fold lower for B6 than D2, in
good agreement with B6-D2 differences in
CYPlAI inducibility in the intact animal,
and two to four times greater than B6-D2
differences reported in in vitro ligand-bind-
ing studies (9,15). In addition, using
chimeric AHRs, we were able to verify in
this biological system the importance ofthe
A375Vchange in generating the low-affinity
phenotype.
The yeast two-hybrid system thus
appears to represent more faithfully the bio-
logical difference in CYPlAl inducibility
phenotype than in vitro ligand-binding
assays. In vitro, the low-affinity forms ofthe
AHR require stabilization by molybdate
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Figure 5. BNF dose-response curves for variant AHR proteins expressed in yeast. Abbreviations: BNF, -
naphthoflavone; AHR, aromatic hydrocarbon receptor; B6, C57BL/6; D2, DBA/2; max, maximum; min, mini-
mum; i, inflection point; s, slope factor. (A) BNF dose-response curves of0-galactosidase activity, repre-
senting BNF activation ofthe B6 and the D2 AHR. All 21 data points for both B6 and D2AHRs were fitted to
the 4-parameter function fix) = (max - min)/[l+ (xj)sl + min. (B) BNF dose-response curves for B6, D2, and
eight B6-D2 chimeric AHRs. These experiments were repeated three times with comparable results; data
from one representative experiment are shown. Curve fits were completed, as described above, using the
data points shown.
(17), whereas in the yeast system this artifi-
cial stabilization of the AHR is not
required, perhaps providing a more accurate
physiological model ofAHR function. In
addition, different AHR phenotypes might
reflect aspects ofAHR activation other than
ligand binding, such as translocation to the
nucleus or dimerization with ARNT (5)
that are not evaluated in the in vitroligand-
binding assays.
The existence of a human AHR poly-
morphism to explain the observedvariability
in CYPlAI inducibility (20-22) and AHR
affinity (2426) has been hypothesized for
many years; however, conclusive evidence to
demonstrate this putative polymorphism is
lacking (23,37,38). Among the B6, D2,
C3H, and Musspretusmouse lines, there are
12 AHR amino acid differences (9-15).
While most amino acid changes were shown
Table2. Median effective concentration (EC50) ± SD
of 0-naphthoflavone induction of B6, D2, and
chimeric aromatic hydrocarbon receptors(AHR)
AHR EC50(nM)
B6 18±4
R 14±2
NMR 9 2*
NM 11 2*
PNMR 10±7*
P 13±4
VPNM 430± 97*
VP 420± 57*
V 330± 45*
D2 260± 23*
Abbreviations: B6, C57BL/6; D2, DBA/2; SD, standard devi-
ation. Results from three independent dose-response
experiments were combined and fitted to a four-parame-
ter function flx) = (max - minl[1+ lWx)51 + min. The EC50
and its SD were determined by nonlinear regression.
*Denotes those EC50 values that are statistically significantly dif-
ferentfrom that ofthe B6AHR (p<0.051.
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to contribute greater than twofold to recep-
tor affinity, the opal mutation contributes
two- to threefold, and the A375V change
contributes four- to sixfold to the differences
in AHR affinity (9,15). It is therefore very
likely that the human AHR polymorphism
will be made up ofat least a dozen, and
probably manymore, amino acid differences
reflecting thevariability inligand affinity.
In this report, we have shown that a
yeast-two hybrid assay can readily determine
phenotypic differences observed between
the B6 and D2 mouseAHRproteins, which
leads us to propose that this system might
be applicable to the analysis of large num-
bers of anticipated differences in human
AHR proteins. The experiments reported
herein only assessed ligand-binding and
dimerization properties, and it is possible
that functional polymorphisms in a human
population may include other steps of the
AHR signaling pathway (5). Expanding the
yeast two-hybrid assay to include a reporter
gene that responds to the transactivating
activity of AHR/ARNT complexes (39)
may provide a unique opportunity to iden-
tify additional steps in the AHR activation
pathway that could be altered and might
thus be reflected in the well-documented
studies about human variation in CYPlAl
inducibiity andAHRaffinity.
Our results demonstrate the utility of
the oligonudeotide hybridization screening
approach for identification ofthe mouseAhr
genotype and ofayeast two-hybrid assay for
quantification ofthe AHRphenotype. Used
together, these two methods constitute a
powerful novel approach to analyze the role
that human AHR polymorphisms might
play in environmentally related diseases
caused by AHR ligands such as dioxin and
BaP.
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